JP2010502576A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502576A5
JP2010502576A5 JP2009525630A JP2009525630A JP2010502576A5 JP 2010502576 A5 JP2010502576 A5 JP 2010502576A5 JP 2009525630 A JP2009525630 A JP 2009525630A JP 2009525630 A JP2009525630 A JP 2009525630A JP 2010502576 A5 JP2010502576 A5 JP 2010502576A5
Authority
JP
Japan
Prior art keywords
fluorophenyl
alkyl
purin
dihydro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502576A (ja
JP5421108B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/018654 external-priority patent/WO2008024438A2/en
Publication of JP2010502576A publication Critical patent/JP2010502576A/ja
Publication of JP2010502576A5 publication Critical patent/JP2010502576A5/ja
Application granted granted Critical
Publication of JP5421108B2 publication Critical patent/JP5421108B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525630A 2006-08-23 2007-08-22 2−フェノキシピリミジノン類縁体 Expired - Fee Related JP5421108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82325806P 2006-08-23 2006-08-23
US60/823,258 2006-08-23
PCT/US2007/018654 WO2008024438A2 (en) 2006-08-23 2007-08-22 2-phenoxy pyrimidinone analogues

Publications (3)

Publication Number Publication Date
JP2010502576A JP2010502576A (ja) 2010-01-28
JP2010502576A5 true JP2010502576A5 (OSRAM) 2010-10-07
JP5421108B2 JP5421108B2 (ja) 2014-02-19

Family

ID=39107411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525630A Expired - Fee Related JP5421108B2 (ja) 2006-08-23 2007-08-22 2−フェノキシピリミジノン類縁体

Country Status (22)

Country Link
US (2) US8003656B2 (OSRAM)
EP (1) EP2061794B1 (OSRAM)
JP (1) JP5421108B2 (OSRAM)
KR (1) KR20090043583A (OSRAM)
CN (2) CN104292229A (OSRAM)
AU (1) AU2007288203B2 (OSRAM)
BR (1) BRPI0716582A2 (OSRAM)
CA (1) CA2660957C (OSRAM)
CO (1) CO6150167A2 (OSRAM)
CR (1) CR10675A (OSRAM)
EA (1) EA200900330A1 (OSRAM)
ES (1) ES2399928T3 (OSRAM)
GT (1) GT200900040A (OSRAM)
IL (1) IL197043A0 (OSRAM)
MA (1) MA30720B1 (OSRAM)
MX (1) MX2009002066A (OSRAM)
NI (1) NI200900023A (OSRAM)
NO (1) NO20091182L (OSRAM)
SV (1) SV2009003173A (OSRAM)
TW (1) TW200825089A (OSRAM)
WO (1) WO2008024438A2 (OSRAM)
ZA (1) ZA200901163B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
AU2007288203B2 (en) 2006-08-23 2013-01-17 Neurogen Corporation 2-phenoxy pyrimidinone analogues
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
SI3417851T1 (sl) 2013-09-09 2020-11-30 Peloton Therapeutics, Inc. Aril etri in njihova uporaba
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20220071953A1 (en) * 2019-01-08 2022-03-10 Texas Tech University System Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
DK0807633T3 (da) 1996-05-15 2002-11-25 Pfizer Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
EP0982992B1 (en) 1997-05-08 2002-09-25 Aventis CropScience UK Limited Use of thienopyrimidines as fungicides
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
AU2002214546A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
CA2433778A1 (en) 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
IL157815A0 (en) 2001-03-26 2004-03-28 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
US20070125454A1 (en) * 2001-09-28 2007-06-07 Konrad Eipper High-strength duplex/triplex steel for lightweight construction and use thereof
EP1461311A2 (en) 2001-12-26 2004-09-29 Bayer HealthCare AG Urea derivatives as vr1-antagonists
ATE533743T1 (de) 2002-05-17 2011-12-15 Janssen Pharmaceutica Nv Harnstoffderivate von aminotetralin als modulatoren des vanilloid-rezeptors vr1
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
AU2003273856A1 (en) 2002-09-24 2004-04-19 Bayer Healthcare Ag Vr1 antagonists for the treatment of urological disorders
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
GB0326633D0 (en) 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
AU2004290626A1 (en) * 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2006122200A1 (en) 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
CN1318429C (zh) * 2005-07-25 2007-05-30 华中师范大学 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3-d]嘧啶-4(3H)-酮及制备
AU2006311883A1 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
AU2007288203B2 (en) 2006-08-23 2013-01-17 Neurogen Corporation 2-phenoxy pyrimidinone analogues
EP2061470A4 (en) 2006-08-23 2010-10-06 Neurogen Corp HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES
CA2668579A1 (en) 2006-11-06 2008-06-05 Neurogen Corporation Cis-cyclohexyl substituted pyrimidinone derivatives
WO2008156607A1 (en) 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
WO2009100403A1 (en) 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
WO2009121036A2 (en) 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives

Similar Documents

Publication Publication Date Title
JP2010502576A5 (OSRAM)
JP2007534687A5 (OSRAM)
JP5997335B2 (ja) N含有複素環式化合物
JP2019052178A (ja) ブロモドメイン阻害剤としての新規の置換された二環式化合物
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
RU2009136299A (ru) Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида
JP2010509224A5 (OSRAM)
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
JP2014528450A5 (OSRAM)
JP2017526711A5 (OSRAM)
JP2008523041A5 (OSRAM)
JP2007510689A5 (OSRAM)
RU2012134306A (ru) Азотосодержащие производные гетероарилов
JP2013523884A5 (OSRAM)
JP2017523223A5 (OSRAM)
JP2016512511A5 (OSRAM)
US20130096149A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
JP2018515525A5 (OSRAM)
CA2737999A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
RU2011125314A (ru) Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
SI3038622T1 (en) Heterocyclic compounds and methods of use
JP2009504792A5 (OSRAM)
JP2017501983A5 (OSRAM)
JP2021500332A5 (OSRAM)
JP2007509158A5 (OSRAM)